A group of researchers wants the American Journal of Psychiatry to retract a study published in 2004 after newly unsealed documents suggest that Forest Laboratories, the company that sold the medicine that was the subject of the study, misled regulators about key details.

As reported previously, the documents indicate the drug maker obscured key data demonstrating its Celexa antidepressant was not effective in children. Instead, the company portrayed the results as positive in materials submitted to regulators in hopes of winning approval for pediatric use.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy